Showing 5241-5250 of 5621 results for "".
- Alcon Launches Advancements to the Centurion Vision System at ASCRShttps://modernod.com/news/alcon-launches-advancements-to-the-centurion-vision-system-at-ascrs/2476556/Alcon introduced new phaco technology that is part of the Centurion Vision System, including the Active Sentry Handpiece and Intrepid Hybrid Tip, at the ASCRS annual meeting. These new products, which are designed to improve safety, consistency and control during cataract surgery,
- Nicox Presents First Data on New Class of Nitric Oxide (NO)-Donating Compounds for Glaucoma at ARVOhttps://modernod.com/news/nicox-presents-first-data-on-new-class-of-nitric-oxide-no-donating-compounds-for-glaucoma-at-arvo/2476545/Nicox SA announced that it has presented the first data from a new drug class designed to lower IOP (NO-donating PDE5 inhibitors) at a poster presentation during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The first
- Alcon to Showcase New Clinical Data, Innovative Technology at ASCRShttps://modernod.com/news/alcon-to-showcase-new-clinical-data-innovative-technology-at-ascrs/2476542/Alcon will feature new clinical data along with innovative product designs and technology for the Cataract Refractive Suite during the American Society of Cataract and Refractive Surgery (ASCRS) 2019 annual meeting, taking place May 3-7 in San Diego. The company, which recently became an independ
- SightGlass Vision Presents Clinical Trial Data From Novel Lenses to Control Myopiahttps://modernod.com/news/sightglass-vision-presents-clinical-trial-data-from-novel-lenses-to-control-myopia/2476541/SightGlass Vision announced that data assessing the tolerability of three iterations of its novel lenses designed to control nearsightedness in children were presented at the Association for Research in Vision and
- Aerie Pharmaceuticals Matches ASCRS Foundation Fund Raising to Provide Sight-Saving Surgeryhttps://modernod.com/news/aerie-pharmaceuticals-matches-ascrs-foundation-fund-raising-to-provide-sight-saving-surgery/2476538/Aerie Pharmaceuticals announced that it is matching, dollar for dollar, the first $30,000 donated to the ASCRS Foundation’s charitable eye care programs by attendees at the 2019 ASCRS-ASOA Annual Meeting, being held in San Diego, from May 3-7, 2019. This is the second year that Aerie is d
- Atia Vision Closes $20M In Series D Financing to Fund Accommodating IOLhttps://modernod.com/news/atia-vision-closes-20m-in-series-d-financing-to-fund-accommodating-iol/2476533/Atia Vision, a Shifamed portfolio company developing a modular presbyopia-correcting accommodating IOL, announced initial closing of its committed $20 million Series D preferred stock
- Jim Wachtman Joins CorneaGen as Chief Commercial Officerhttps://modernod.com/news/jim-wachtman-joins-corneagen-as-chief-commercial-officer/2476527/CorneaGen announced that James “Jim” C. Wachtman has joined the young company as chief commercial officer. Mr. Wachtman has been a leader in the cornea community for 20 years and serves as the chair of the Refractive Surgery Council, a group of industry manufacturers and ophthalmologists focused
- Verseon Presents Oral Drug Candidate for Diabetic Eye Diseasehttps://modernod.com/news/verseon-presents-oral-drug-candidate-for-diabetic-eye-disease/2476516/Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injecti
- Sight Sciences Announces Launches of TearCare and the Enhanced OMNI Systemhttps://modernod.com/news/sight-sciences-announces-official-launches-of-tearcare-and-the-enhanced-next-generation-omni-system/2476517/Sight Sciences announced the official commercial launch of TearCare and the introduction of an aesthetically and ergonomically enhanced OMNI Surgical System, which was initially launched in February 2018. The rollout of the new devices will include product dem
- Bausch + Lomb Announces Update From Antibiotic Resistance Monitoring in Ocular Microorganism (ARMOR) Studyhttps://modernod.com/news/bausch-lomb-announces-update-from-antibiotic-resistance-monitoring-in-ocular-microorganism-armor-study/2476512/Bausch + Lomb announced the results from nearly 10 years of the ARMOR (Antibiotic Resistance Monitoring in Ocular Microorganisms) surveillance study, presented at the ARVO meeting in Vancouver. Researchers also presented preliminary 2018 surveillance data on antibiotic resistance levels. Initiate